publicli
fund
repositori
covid
databas
right
unrestrict
research
reus
analys
form
mean
acknowledg
origin
sourc
permiss
grant
free
elsevi
long
resourc
centr
remain
activ
fibromyalgia
syndrom
pain
modul
disord
relat
alter
limbic
function
physician
special
diagnosi
treatment
chronic
fatigu
syndrom
cf
fibromyalgia
syndrom
fm
see
larg
number
patient
also
problem
irrit
bowel
syndrom
panic
disord
amnest
disord
allerg
rhiniti
blur
vision
muscl
fascicul
myasthenia
interstiti
cystiti
sleep
disord
headach
bruxism
irrit
bladder
alopecia
thermoregulatori
dysfunct
lymphadenalgia
dyspnoea
chemic
sensit
endometriosi
late
luteal
phase
dysphor
disord
heart
palpit
photophobia
vertigo
raynaud
phenomenon
dysmenorrhoea
patient
immun
activ
relat
overlap
syndrom
disord
system
lupu
erythematosu
multipl
sclerosi
half
report
feel
well
worst
flu
life
never
felt
investig
persist
viral
infect
hit
run
viral
episod
result
longterm
function
impair
affect
bystand
cell
relev
quit
common
consult
individu
mani
disord
initi
seem
unrel
look
mechan
produc
wide
rang
ill
led
studi
neuroimmunoendocrin
network
especi
limbic
system
project
myriad
sign
symptom
may
explain
limbic
dysfunct
literatur
discuss
structur
function
limbic
system
cortic
project
figur
exampl
neural
network
use
parallel
distribut
comput
strategi
complex
may
unfamiliar
mani
reader
volum
topic
well
discuss
mmarsel
mesulam
work
form
good
foundat
understand
limbic
physiolog
derang
one
view
limbic
neural
network
function
comput
process
interoand
exterocept
stimuli
input
primarili
via
bewild
array
chemic
transduc
messag
integr
experi
attitud
process
select
respons
output
ideal
maxim
surviv
capabl
individu
figur
scientif
american
inc
right
reserv
limbic
system
highest
order
function
regul
integr
process
bodi
effect
fatigu
pain
sleep
weight
appetit
libido
respir
temperatur
blood
pressur
memori
attent
concept
format
mood
vigil
immun
endocrin
system
modul
peripher
nervou
system
name
limbic
dysregul
function
could
derang
sinc
neurobiolog
mechan
limbic
function
disord
shall
use
term
neurosomat
describ
complex
regulatori
system
could
mani
specif
area
vulner
dysfunct
could
primari
central
aetiolog
could
occur
respons
peripher
stressor
variou
sort
sinc
limbic
system
involv
select
adapt
respons
stress
stress
could
defin
event
could
alter
actual
perceiv
homeostasi
rang
stimuli
could
caus
limbic
dysregul
larg
could
process
sensori
input
aberr
cfsfm
result
dysfunct
respons
weight
given
variou
sensat
seem
increas
perhap
account
phonophobia
photophobia
odor
sensit
mani
patient
complain
figur
weight
given
sensori
input
call
sensori
gate
studi
examin
startl
reflex
inhibit
startl
stimulu
preced
weak
prepuls
phenomenon
term
prepuls
inhibit
ppi
studi
anim
schizophren
techniqu
also
use
see
whether
men
differ
women
degre
inhibit
prepuls
bickford
et
al
swerdlow
et
al
b
anim
studi
implic
hippocampu
represent
neuron
process
activ
signal
input
activ
multipli
number
call
weight
unit
add
togeth
weight
input
comput
output
activ
use
inputoutput
function
figur
adapt
page
hinton
g
neural
network
learn
experi
scientif
american
septemb
scientif
american
inc
right
reserv
reticular
format
ppi
women
inhibit
less
well
men
research
schizophren
yield
consist
result
studi
cf
patient
use
techniqu
found
pilot
studi
patient
abnorm
waveform
unpublish
result
result
hold
may
repres
diagnost
test
cfsfm
treatment
discuss
chapter
may
markedli
improv
ppi
deficit
abl
perform
doubleblind
placebocontrol
experi
lack
fund
possibl
observ
pharmacolog
effect
thse
medic
reproduc
alter
neurochem
neurophysiolog
paramet
caus
placebo
administr
peck
coleman
like
fm
commonli
comorbid
anxieti
fatigu
migrain
headach
irrit
bowel
syndrom
ib
goldenberg
common
neurobiolog
mechan
almost
certainli
supraspin
pain
major
symptom
fm
well
ib
cf
migrain
headach
numer
descend
inhibitori
pathway
brainstem
eg
raph
nuclei
locu
ceruleu
periaqueduct
grey
reticular
format
well
higher
centr
hypothalamu
thalamu
limbic
system
cortic
structur
regul
pain
higher
centr
poorli
understood
tasker
dostrovski
coderr
et
al
muscl
fatigu
cf
appear
central
kentbraun
et
al
pain
fatigu
dysregul
mani
neural
network
function
increas
tendenc
view
fm
cf
variabl
present
pathophysiolog
process
wayloni
heck
goldstein
appear
neurobiolog
one
third
cf
patient
meet
tender
point
criteria
fm
numer
neurochem
abnorm
describ
cfsfm
basic
find
low
level
central
corticotrophinreleas
hormon
crh
polypeptid
central
nervou
system
cn
function
besid
regul
proopiomelanocortin
adrenocorticotroph
hormon
acth
secret
involv
regul
sympathet
nervou
system
well
prefront
cortex
fisher
takamatsu
et
al
beta
beta
pluripotenti
cytokin
regul
crh
secret
prostaglandin
alpha
rothwel
cerebrospin
fluid
csf
beta
level
normal
studi
cf
patient
lloyd
et
al
well
fm
cohort
ij
russel
person
commun
suggest
antagon
beta
effect
crh
also
stimul
agent
see
postul
decreas
effect
leav
increas
csf
substanc
p
level
et
al
poorli
explain
sinc
known
stimul
substanc
p
secret
martin
et
al
substanc
p
howev
inhibit
releas
crh
larsen
et
al
also
unmask
connect
dorsal
horn
may
involv
format
new
recept
field
hoheisel
et
al
use
model
decreas
central
beta
effect
result
decreas
secret
crh
peripher
immun
activ
found
cf
account
saperstein
et
al
sinc
crh
immunosuppress
virtu
stimul
cortisol
secret
well
sympathet
activ
spleen
region
lymphat
organ
beta
may
howev
stimul
secret
biogen
amin
directli
without
prostaglandin
involv
elev
crh
level
shintani
et
al
use
exercis
ergometri
stressor
patient
cfsfm
compar
illregul
function
preand
postexercis
done
other
griep
et
al
fail
find
expect
increas
cortisol
catecholamin
growth
hormon
betaendorphin
somatostatin
core
bodi
temperatur
exercis
goldstein
result
markedli
differ
found
normal
anxiou
group
exercis
adolesc
gerra
et
al
hyperventil
common
among
cf
patient
greater
fibromyalgia
tender
point
mark
irregular
tidal
volum
maxim
exercis
find
previous
report
regul
automat
respir
function
limbic
system
munschauer
et
al
sort
abnorm
evid
limbic
dysfunct
cfsfm
goldstein
et
al
other
ichis
et
al
mountz
et
al
found
brain
singl
photon
emiss
computer
tomographi
spect
technetium
hexamethyl
propyleneamin
oxim
hmpao
measur
region
cerebr
blood
flow
rcbf
abnorm
cf
patient
cfsfm
studi
region
hypoperfus
anterior
tempor
dorsolater
prefront
right
hemispher
wors
left
cf
patient
without
fm
fm
patient
sever
hypoperfus
cfsfm
patient
significantli
differ
pattern
perfus
match
comparison
group
depress
consist
find
rcbf
measur
use
decreas
exercis
popul
opposit
occur
normal
mena
research
increasingli
point
genet
propens
develop
cfsfm
found
significantli
increas
patient
compar
normal
p
goldstein
other
klima
middleton
et
al
confirm
find
clinician
see
larg
number
patient
note
increas
famili
incid
panic
disord
hudson
et
al
famili
comorbid
disord
highest
occurr
panic
disord
gener
believ
predominantli
limbic
mechan
caplan
et
al
howev
hereditari
predisposit
develop
certain
ill
may
rang
strong
weak
strong
tendenc
afflict
cfsfm
may
sick
sinc
childhood
other
may
requir
one
trigger
stimuli
child
abus
viral
infect
surgeri
pronounc
physic
mental
overexert
childbirth
emot
stress
fairli
well
accept
victim
child
abus
like
develop
somat
symptom
adult
fri
sinc
limbic
system
primari
mediat
stress
respons
reason
assum
function
chang
may
long
last
could
occur
neuron
network
teicher
et
al
hypercortisolaemia
prolong
stress
may
damag
neuron
cornu
ammoni
area
region
hippocampu
alter
regul
hippocamp
corticosteroid
receptor
effect
may
amelior
cn
calcium
channel
blocker
nimodipin
levi
et
al
chang
may
occur
transmitt
receptor
also
second
messeng
cascad
transcript
factor
peptid
protein
growth
factor
post
viral
infect
affect
patient
differ
perhap
depend
viral
sequenc
process
present
individu
may
present
epitop
other
virus
may
produc
latent
infect
caus
immun
respons
joli
et
al
may
alter
secret
one
neurotransmitt
oldston
may
caus
hit
run
infect
longlast
alter
cellular
function
occur
viru
disappear
demitrack
greden
viral
induc
neurotransmitt
deficit
may
correct
appropri
medic
mehta
et
al
latent
herpesviru
infect
well
known
exist
nerv
ganglia
appear
time
stress
bonneau
et
al
trigemin
nerv
modul
limbic
activ
project
pontin
reticular
format
hypothalamu
burstein
et
al
commonli
involv
product
herp
labiali
exampl
herp
simplex
common
viru
infect
limbic
system
usual
anterior
tempor
cortex
virus
may
enter
limbic
system
via
retrograd
neuron
transport
lavi
et
al
thu
viral
infect
could
alter
neuron
function
genet
vulner
person
may
alreadi
premorbid
limbicrel
disord
bruxism
ib
allerg
rhiniti
way
function
neural
network
could
dysregul
sensori
gate
process
abnorm
would
becom
manifest
derang
respons
produc
symptom
aspect
viral
infect
relev
cfsfm
given
tabl
thu
far
singl
viral
candid
precipit
cf
perhap
multipl
agent
could
implic
human
immunodefici
viru
hiv
glycoprotein
block
receptor
also
vasoact
intestin
peptid
vip
receptor
vip
stimul
product
nerv
growth
factor
buzi
et
al
well
nitric
oxid
yamamoto
et
al
alpha
beta
tabl
aspect
viral
infect
relev
cfsfm
one
viru
may
involv
two
virus
may
interact
enhanc
virul
process
known
transactiv
well
known
human
human
immunodefici
viru
viral
gene
product
host
gene
product
may
interact
well
viral
gene
product
andor
cellular
product
may
affect
bystand
cell
product
may
cytokin
glycoprotein
hiv
infect
transmitt
substanc
may
also
caus
system
effect
immun
activ
act
distanc
viral
infect
may
also
caus
decreas
secret
cellular
product
superantigen
may
produc
viral
gene
product
bind
variabl
segment
tcell
receptor
major
histocompat
complex
molecul
caus
fairli
nonspecif
immun
activ
bacteri
exotoxin
may
also
act
superantigen
toxic
shock
syndrom
postinfecti
arthrit
disord
suggest
caus
superantigen
sisson
encephalopathi
also
possibl
also
block
neuron
ltype
calcium
channel
process
prevent
nimodipin
central
act
dihydropyridin
calciumchannel
blocker
stefano
et
al
vip
import
neuron
surviv
suggest
antagon
vip
respons
hiv
cognitivemotor
complex
often
first
manifest
acquir
immunodefici
syndrom
aid
peptid
synthet
vip
analogu
may
use
block
central
effect
use
nimodipin
hiv
encephalopathi
investig
cognit
dysfunct
could
similarli
occur
patient
cfsfm
persist
hitandrun
viral
infect
implic
pathogenesi
could
even
occur
de
novo
genet
differ
hla
haplotyp
may
determin
antigen
determin
epsteinbarr
viru
caus
immun
activ
de
camposlima
et
al
variabl
epitop
would
variabl
immun
respons
perhap
account
conundrum
popul
develop
acut
infecti
mononucleosi
similar
consider
could
appli
develop
cfsfm
presum
pathophysiolog
cfsfm
limbic
neural
network
disord
suggest
use
pharmacolog
probe
explor
therapeut
approach
trigemin
nerv
may
view
major
integr
somat
viscer
input
spinal
cervic
cranial
nerv
synaps
spinal
mesencephal
trigemin
nerv
tract
trigemin
nerv
may
produc
expans
recept
field
zone
wide
dynam
rang
nociceptivespecif
neuron
certain
condit
greater
number
neuron
activ
stimul
recept
zone
caus
innocu
stimuli
perceiv
pain
dubner
fromm
et
al
work
done
spinal
cord
dorsal
horn
could
also
appli
rostral
caudal
trigemin
nerv
nuclei
especi
trigemin
subnucleu
caudali
consid
homologu
spinal
dorsal
horn
research
focus
mainli
peripher
noxiou
stimuli
appli
central
process
deafferent
pain
phantom
limb
syndrom
melzack
numer
way
modul
trigemin
nerv
activ
one
use
adrenerg
eyedrop
naphazolin
hydrochlorid
vasocon
naphcon
etc
one
drop
place
eye
patient
assess
later
one
third
patient
signific
relief
pain
tender
point
sensit
well
decreas
fatigu
mental
clariti
cfsfm
patient
promin
anxieti
symptom
respond
best
treatment
patient
may
tri
understand
mechan
action
perform
preand
posttreat
brain
spect
signific
diminut
rcbf
drop
first
eye
becom
profound
second
eye
instil
respons
ipsilater
would
occur
stimul
trigemin
neurovascular
system
caus
vasodil
one
hemispher
propos
multisynapt
pathway
mesencephal
trigemin
tract
pontin
reticular
format
andor
hypothalamu
thalam
reticular
nuclei
subsequ
cortex
limbic
system
perhap
hippocampu
goldstein
sensori
input
produc
touch
pain
transmit
thalamu
separ
pathway
travel
cortex
singl
project
pain
occur
touch
neurotransmiss
thalamu
inhibit
gabaerg
interneuron
thalam
reticular
nuclei
impair
thalam
gammaaminobutyr
acid
gaba
secret
could
result
touch
sensat
perceiv
cortex
noxiou
could
one
mechan
central
pain
barinaga
benzodiazepin
alprazolam
enhanc
effect
gaba
could
act
thalamu
reduc
central
pain
fm
naphazolineinduc
cerebr
vasoconstrict
may
due
releas
neuroact
substanc
also
affect
arteri
tone
transmitt
secret
endothelium
well
cell
type
would
like
candid
list
endogen
cerebr
vasoconstrictor
shorter
vasodil
includ
noradrenalin
nenropeptid
endothelin
thromboxan
receptor
antagonist
protein
angiotensin
ii
vasopressin
serotonin
depend
serotonin
receptor
involv
matsui
et
al
peticlerc
et
al
uddman
et
al
nonadrenerg
ophthalm
agent
usual
effect
except
proxymetacain
proparacain
usp
sometim
transient
reduc
pain
fm
tout
treatment
trigemin
neuralgia
zavonik
ficht
proxymetacain
may
work
decreas
excess
fire
lowthreshold
mechanocept
neuron
spinal
trigemin
nucleu
orali
fromm
somewhat
unusu
publish
report
brain
function
imag
see
worsen
hypoperfus
correl
symptomat
improv
sinc
cerebr
metabol
blood
flow
directli
relat
region
rate
perfus
regul
tightli
correspond
level
substrat
demand
metabol
activ
howev
imipramin
produc
cerebr
hypoperfus
lottenberg
endothelin
increas
cerebr
metabol
uncoupl
blood
flow
sinc
power
cerebr
vasoconstrictor
gross
et
al
hypermetabol
activ
mediat
ltype
calcium
channel
inhibit
nimodipin
endothelin
amino
acid
peptid
discov
three
endothelin
two
endothelin
receptor
type
eta
etb
endothelin
receptor
found
neuron
neuroendocrin
endocrin
cell
well
endotheli
cell
endothelin
promot
releas
vasopressin
substanc
p
lutein
hormon
folliclestimul
hormon
prolactin
growth
hormon
rapid
develop
sensit
prolong
repetit
stimul
endothelin
usual
probabl
endocytosi
endothelinreceptor
complex
stojilkov
catt
toler
naphazolin
ophthalm
solut
common
agent
may
stimul
endothelin
secret
see
perhap
pertin
cfsfm
endothelin
stimul
crh
neuron
hirai
et
al
complic
issu
somewhat
act
etb
receptor
vasodilatori
gener
prostacyclin
nitric
oxid
endotheliumdepend
hyperpolar
factor
distinct
nitric
oxid
hayn
et
al
act
eta
receptor
stimul
neuron
releas
dopamin
kurosawa
et
al
neurotransmitt
import
regul
mood
activ
effect
dopamin
rcbf
somewhat
similar
action
peripher
circul
low
dose
caus
vasodil
high
dose
produc
vasoconstrict
koyama
et
al
grasbi
et
al
dopaminereleas
properti
thu
far
studi
relat
product
ischaemia
attenu
calcium
channel
blocker
ooboshi
et
al
hydralazin
fux
et
al
sometim
effect
treatment
cfsfm
given
intracerebroventricular
inject
mice
produc
longlast
dosedepend
antinocicept
antagon
naloxon
nikolov
et
al
high
densiti
endothelin
receptor
hypothalamu
limbic
system
csf
endothelin
level
measur
patient
depress
normal
control
hoffman
et
al
endothelin
level
depress
group
half
control
popul
endothelin
thought
paracrin
factor
normal
involv
longterm
cellular
regul
may
import
sever
patholog
mani
stressrel
huggin
et
al
numer
endothelin
agonist
synthes
huggin
et
al
agent
appropri
receptor
specif
may
use
treatment
neurosomat
disord
nitric
oxid
primari
vasodil
brain
might
serv
diffus
signal
within
neuron
tissu
necessari
releas
catecholamin
possibl
neurotransmitt
evok
axon
termin
propos
function
would
addit
three
role
substanc
vertebr
nervou
system
regul
local
blood
flow
regul
synapt
efficaci
segreg
axon
arbor
basi
neuron
activ
hanbauer
et
al
synthas
fairli
ubiquit
enzym
heavili
concentr
hippocampu
valtschanoff
et
al
well
rostral
ventrolater
medulla
anoth
site
sensori
gate
iadecola
et
al
hippocampu
anoth
gaseou
neurotransmitt
carbon
monoxid
serv
retrograd
messeng
produc
activitydepend
presynapt
enhanc
longterm
potenti
zhuo
et
al
put
retrograd
messeng
difficult
suppli
exogen
includ
arachidon
acid
plateletactiv
factor
zorumski
izumi
longterm
potenti
last
hour
day
refer
prolong
chang
target
neuron
result
intens
brief
train
stimuli
deliv
presynapt
neuron
saw
profound
region
cerebr
hypoperfus
cfsfm
brain
spect
one
first
inclin
revers
best
avail
market
sourc
glyceryl
trinitr
exert
vasodilatori
action
convers
give
cfsfm
patient
low
mg
dose
sublingu
glyceryl
trinitr
sometim
result
amelior
symptom
especi
pain
rain
also
effect
central
pain
deafferent
syndrom
reflex
sympathet
dystrophi
patient
fail
back
syndrom
often
respond
toler
effect
glyceryl
trinitr
often
develop
vasodil
still
occur
one
would
expect
consider
cerebr
vasodil
brain
spect
glyceryl
trinitr
alway
case
sometim
actual
vasoconstrict
sometim
releas
endothelin
decreas
vasoconstrict
stimul
endothelin
releas
webb
result
suggest
symptomat
improv
cfsfm
depend
revers
hypoperfus
posttreat
blood
flow
chang
epiphenomena
perhap
contribut
effect
human
endotheli
cell
synthes
releas
inhibitor
product
fickl
agent
use
vasodil
appear
effect
rcbf
cfsfm
patient
summat
intrins
vasodil
capabl
whatev
vasoconstrictor
concomitantli
releas
naphazolin
howev
adrenerg
agonist
eye
alway
result
cerebr
vasoconstrict
patient
benefici
effect
although
result
endproduct
multisynapt
pathway
patient
respond
naphazolin
littl
reduct
rcbf
influenc
transmitt
secret
mani
type
neuron
difficult
pin
role
cfsfm
enter
fire
presynapt
neuron
retrograd
diffus
stimul
guanylyl
cyclas
produc
cyclic
guanosin
monophosph
gmp
kandel
hawkin
latter
compound
induc
glutam
secret
diffus
neuron
alreadi
secret
neurotransmitt
potenti
signal
particular
microneur
network
process
call
longterm
potenti
ltp
ltp
studi
hippocampu
relat
make
new
memori
function
impair
neuropsycholog
test
cfsfm
patient
increas
synapt
strength
type
neural
assembl
may
import
aspect
cfsfm
treatment
cfsfm
may
also
view
synapt
converg
defici
syndrom
converg
defin
process
neuron
stronger
connect
fewer
target
cell
greenough
bailey
role
ltp
could
exampl
converg
serotonerg
agent
often
use
cfsfm
applic
serotonin
ltp
paradigm
mimic
behaviour
electrophysiolog
effect
ltp
produc
longterm
enhanc
synapt
efficaci
patterson
shortterm
memori
encod
poor
cf
consid
deficit
diagnost
sandman
et
al
ltp
also
occur
frontal
cortex
bear
kirkwood
impair
secret
could
detract
precis
interneuron
commun
region
twelv
fm
patient
symptom
besid
pain
test
see
whether
encod
problem
present
patient
evid
deficit
although
none
awar
ja
goldstein
ca
sandman
unpublish
result
encod
deficit
often
respond
rapidli
dramat
treatment
discuss
chapter
anxiolyt
chlordiazepoxid
effect
administ
mice
pretreat
synthas
inhibitor
chlordiazepoxid
action
return
mice
given
harginin
precursor
quock
nguyen
releas
dopamin
hanbauer
et
al
could
reliev
fatigu
produc
behaviour
stimul
well
enhanc
cognit
attent
also
increas
releas
serotonin
lorrain
hull
stimul
secret
vip
secret
also
stimul
vip
grider
jin
may
coloc
vip
found
trigemin
ganglion
neuropeptid
cerebr
vasoconstrictor
neuropeptid
highest
concentr
brain
releas
primarili
limbic
cortic
region
heilig
widerlov
anxiolyt
coloc
noradrenerg
neuron
known
stimul
appetit
caus
weight
gain
independ
effect
appetit
heinrich
et
al
invers
relationship
crh
howev
thu
like
stimul
drug
effect
cfsfm
certain
circumst
neuropeptid
releas
kobari
et
al
coloc
nozaki
et
al
partli
indirect
dopaminerg
effect
increas
morphin
withdraw
symptom
adult
male
rat
adam
et
al
morphin
treatment
stimul
synthesi
ferreira
et
al
increas
morphinerel
behaviour
chang
mice
calignano
et
al
perhap
relat
effect
opioid
increas
dopamin
releas
corpu
striatum
antinocicept
induc
intracerebroventricular
may
potenti
betaendorphin
mu
gamma
kappa
agonist
thu
thought
involv
descend
pain
inhibit
xu
tseng
fibromyalgia
patient
report
glyceryl
trinitr
significantli
potenti
effect
durat
opioid
analges
neuron
synthas
activ
calciumdepend
mechan
also
stimul
beta
known
certain
whether
latter
mechan
constitut
brain
decreas
region
level
could
relat
decreas
beta
product
inhibit
action
cytokin
neuropeptid
goldstein
mechan
could
also
produc
lower
level
cn
serotonin
dopamin
certain
prostaglandin
crh
beta
messeng
rna
mrna
receptor
antagonist
protein
mrna
dens
local
dorsal
raph
nuclei
synthes
serotonin
e
de
person
commun
antinocicept
effect
brain
opposit
found
spinal
cord
nmethyldaspart
nmda
receptor
activ
implic
nocicept
process
meller
gebhart
mani
effect
nmda
receptor
activ
appear
mediat
sinc
glutam
primari
ligand
nmda
receptor
thermal
hyperalgesia
anim
potenti
caus
increas
cyclic
gmp
thu
increas
glutam
nmda
receptor
antagonist
synthas
inhibitor
develop
novel
analges
woolf
thompson
thu
appear
peripffer
thermal
pain
process
modul
opposit
manner
central
pain
certainli
glyceryl
trinitr
effect
peripher
noxiou
stimul
patient
corollari
hypothesi
nomodul
sensori
gate
cfsfm
occur
rostral
dorsal
horn
nmda
receptor
antagonist
given
intracerebroventricular
rout
shown
attenu
antinocicept
effect
nmda
receptor
antagonist
given
intrathec
would
primarili
spinal
site
action
nasstrom
et
al
explan
similar
propos
b
yunu
ie
pain
fibromyalgia
result
central
sensori
dysregul
yunu
yunu
conceiv
heterogen
neurohormon
dysfunct
primari
problem
describ
peripher
supraspin
structur
interact
level
dorsal
horn
caus
sensori
gate
abnorm
view
dorsal
horn
one
mani
sensori
gate
might
dysfunct
rostral
spinal
cord
expans
yunu
basic
concept
would
better
explain
wide
varieti
symptom
specif
find
function
imag
brain
neuropsycholog
test
patient
myalgic
encephalomyel
british
commonwealth
term
cf
found
red
blood
cell
alter
shape
nondiscocyt
cup
form
simpson
red
cell
less
deform
normal
proper
concentr
howev
preserv
enhanc
red
cell
deform
korbut
gryglewski
although
found
mainli
parasympathet
neuron
potent
stimul
acetylcholin
also
found
sympathet
postganglion
neuron
cell
bodi
respons
vasodil
antagonist
use
lewi
et
al
also
coloc
substanc
p
calcitonin
generel
peptid
vasodil
substanc
produc
trigemin
vascular
system
edvinsson
et
al
note
sever
year
cfsfm
patient
like
develop
endometriosi
averag
individu
goldstein
cf
monocyt
behav
like
monocyt
control
prieto
et
al
defect
revers
vitro
naloxon
one
caus
endometriosi
failur
monocytesmacrophag
ingest
endometrium
normal
reflux
fallopian
tube
menstruat
cf
patient
may
like
defect
especi
sinc
cytotox
macrophag
peritoneum
relat
macrophag
abil
produc
sotomayor
et
al
femal
patient
cfsfm
usual
premenstru
exacerb
symptom
symptom
late
luteal
phase
dysphor
disord
similar
cf
like
disord
limbic
aetiolog
similar
cfsfm
neural
system
adapt
chang
demand
environ
modul
intrins
membran
properti
neuron
strength
synapt
connect
kennedi
marder
recent
year
found
adult
brain
much
plastic
neuron
circuit
previous
thought
ongo
morpholog
chang
occur
dendrit
modifi
synapt
commun
neuron
glia
synaps
densiti
adult
mammalian
hippocamp
neuron
found
fluctuat
depend
circul
level
oestradiol
adult
primat
oestradiol
valer
treatment
result
decreas
number
axosomat
synaps
infundibular
hypothalam
nucleu
naftolin
et
al
possibl
exampl
synapt
converg
variat
synaps
densiti
could
account
cognit
dysfunct
associ
late
luteal
phase
dysphor
disord
decreas
effici
synapt
gate
sensori
input
process
mechan
effect
oestradiol
uncertain
present
calciumchannel
blocker
act
variou
site
ltype
calcium
channel
inhibit
calcium
influx
neuron
depolar
certain
circumst
may
also
inhibit
calcium
efftux
properti
demonstr
calciumchannel
blocker
nimodipin
azmitia
et
al
ltype
calcium
channel
wide
distribut
brain
central
action
calciumchannel
blocker
well
known
prophylaxi
migrain
one
class
ltype
calciumchannel
blocker
dihydropyridin
includ
isradipin
nifedipin
nicardipin
felodipin
nitrendipin
nisoldipin
amlodipin
nimodipin
drug
slightli
differ
other
nimodipin
use
primarili
effect
counteract
cerebr
vasospasm
subarachnoid
haemorrhag
sinc
fewer
system
hypotens
effect
dihydropyridin
lipophil
enabl
cross
bloodbrain
barrier
easili
nicardipin
better
cerebr
vasodil
alborch
et
al
lower
blood
pressur
much
prescrib
acut
ill
patient
ruptur
aneurysm
may
howev
neuroprotect
effect
nimodipin
subarachnoid
haemorrhag
relat
vasodil
mechan
tettenborn
fieru
found
nimodipin
uniqu
effect
among
drug
class
manag
cfsfm
also
use
treatmentresist
panic
disord
gibb
relat
limbic
dysfunct
neuron
plastic
relat
calciumdepend
preand
postsynapt
process
occur
ltp
hippocampu
ginspen
nimodipin
strongli
enhanc
fire
rate
singl
age
hippocampu
neuron
record
vivo
two
calciumchannel
blocker
nifedipin
flunarizin
disterhoft
et
al
mg
nimodipin
capsul
usual
work
min
often
produc
relax
increas
energi
decreas
tender
point
sensit
improv
exercis
toler
enhanc
mental
clariti
calciumchannel
blocker
sort
previous
report
use
panic
disord
goldstein
klein
uhd
potenti
opioid
analges
pereira
et
al
nimodipin
also
investig
treat
hiv
cognitivemotor
complex
calciumchannel
blocker
potenti
action
lignocain
lidocain
usp
taniguchi
et
al
analges
monotherapi
given
epidur
dey
et
al
topic
eye
chen
et
al
patient
development
learn
disord
remark
improv
nimodipin
drug
also
antidepress
effect
patient
anim
model
de
jong
et
al
besid
bind
receptor
irrevers
bind
ltype
neuron
calcium
channel
inhibit
cellular
chemotaxi
bind
antagon
nimodipin
stefano
et
al
also
sequenc
homolog
crh
relat
induct
acth
lymphocyt
hiv
stefano
et
al
possibl
could
endogen
analogu
sequenc
peptid
could
neurotox
gene
product
produc
virus
could
trigger
cfsfm
obvious
crh
agonist
one
product
twothird
time
nimodipin
caus
vasoconstrict
posttreat
cfsfm
brain
spect
sometim
profound
degre
paradox
respons
anoth
demonstr
therapeut
benefit
cfsfm
deriv
releas
substanc
intrins
vasoconstrict
properti
nimodipin
shown
releas
dopamin
serotonin
acetylcholin
azmitia
et
al
fanelli
et
al
rezvani
et
al
transmitt
serotonin
vasoconstrict
human
brain
physiolog
concentr
toler
develop
vasodilatori
properti
nimodipin
sometim
effect
cfsfm
caus
releas
substanc
known
increas
secret
endothelin
compound
includ
angiotensin
ii
thrombin
bradykinin
adenosin
triphosph
atp
acth
plateletactiv
factor
cytokin
vasopressin
variou
growth
factor
includ
transform
growth
factor
beta
tgf
beta
stojilkov
catt
insulinlik
growth
factor
igf
matsumoto
et
al
none
known
defici
cfsfm
except
igf
prescrib
vasopressin
form
desaminodarginin
vasopressin
ddavp
numer
patient
year
minim
result
also
combin
fenfluramin
secretagogu
attempt
increas
crh
secret
effect
vasopressin
level
actual
elev
cf
g
chrouso
person
commun
tgf
beta
anyth
elev
cf
goldstein
chao
et
al
angiotensinconvert
enzym
ace
inhibitor
captopril
effectiy
antidepress
zubenko
nixon
limit
util
amelior
cfsfm
symptom
probabl
captopril
endopeptidas
inhibitor
increas
concentr
certain
peptid
includ
enkephalin
ace
inhibitor
also
increas
bradykinin
secret
increas
endothelin
level
well
stimul
releas
endotheli
cell
captopril
ace
inhibitor
sulphydryl
group
also
market
agent
class
antidepress
properti
reason
hydralazin
thought
dilat
arteri
stimul
cyclic
gmp
nathanson
work
via
notyp
mechan
began
use
therapeut
trial
cfsfm
respond
report
amelior
one
target
symptom
within
hour
dose
hydralazin
also
report
potenti
effect
nitrovasodil
vascular
smooth
muscl
prior
cyclat
activ
hypothes
hydralazin
inhibit
pyridoxaldepend
reaction
inactiv
sulphydryl
group
thought
involv
action
glyceryl
trinitr
unger
et
al
inde
methionin
cystein
sulphurcontain
amino
acid
advoc
revers
nitrat
toler
help
cfsfm
popul
patient
benefit
hydralazin
also
worsen
arteri
vasoconstrict
posttreat
brain
spect
muscl
weak
cf
may
sometim
treat
pyridostigmin
bromid
manner
similar
use
myasthenia
gravi
surprisingli
pyridostigmin
cholinesteras
inhibitor
cross
bloodbrain
barrier
may
allevi
mental
foggi
increas
energi
reduc
pain
drug
report
increas
secret
growth
hormon
arvat
et
al
potenti
growth
hormonereleas
hormon
via
central
cholinerg
mechan
somatomedin
growth
hormon
relat
peptid
found
low
patient
fm
bennett
et
al
note
previous
igf
may
increas
central
secret
endothelin
pyridostigmin
may
also
induc
adren
gland
secret
corticosteroid
catecholamin
could
act
alter
peripher
autonom
input
cn
mexiletin
introduc
type
iib
antiarrhythm
major
site
action
brain
relat
lignocain
tocainid
seriou
advers
reaction
low
dose
recent
mexiletin
use
success
neuropath
pain
particularli
dysaesthesia
mode
action
unknown
may
act
increas
central
crh
secret
calgero
et
al
lignocain
procain
act
local
anaesthet
sodium
channel
action
hypothalamu
stimul
crh
independ
effect
sodium
conduct
mexiletin
also
block
releas
substanc
p
mous
spinal
nocicept
termin
kame
et
al
possibl
mechan
action
medic
discuss
chapter
could
stimul
endothelin
releas
subsequ
enhanc
crh
secret
crh
might
also
stimul
directli
sinc
crh
enhanc
peripher
sympathet
neurotransmiss
given
central
may
caus
cerebr
arteri
vasoconstrict
directli
caus
releas
noradrenalin
stimul
crh
block
one
experiment
model
rivier
howev
result
could
support
facilitatori
role
crh
secret
least
illdepend
process
local
anaesthet
also
shown
inhibit
uptak
cholin
noradrenalin
gaba
sever
humanor
ratderiv
clonal
cell
line
luka
bencherif
would
possibl
continu
pharmacolog
litani
cite
hz
receptor
antagonist
serotonin
receptor
subtyp
agonist
antagonist
cyclic
antidepress
serotonin
reuptak
inhibitor
monoamin
oxidas
inhibitor
bupropion
neuroact
steroid
host
central
act
agent
goldstein
doubleblind
placebocontrol
test
drug
perform
lack
fund
clinician
may
wish
tri
sequenti
individu
patient
see
appendix
basic
point
wish
convey
howev
disord
regulatori
physiolog
import
limbic
compon
thu
far
seem
involv
sensori
gate
process
sensori
input
probabl
multifactori
aetiolog
region
limbic
neural
network
affect
way
function
neuron
machineri
derang
markedli
influenc
patient
symptomatolog
rapid
respons
medic
describ
concomit
profound
posttreat
alter
brain
spect
suggest
least
neurophysiolog
basi
mani
neurosomat
disord
may
improv
amelior
statedepend
derang
neural
network
function
agent
tri
sequenti
onset
action
durat
action
naphazolin
hydrochlorid
one
drop
eye
glyceryl
trinitr
mg
sublingu
h
nimodipin
mg
mouth
h
mexiletin
mg
mouth
h
pyridostigmin
mouth
hydralazin
mouth
ranitidin
bid
doxepin
hydrochlorid
elixir
mg
hs
variabl
sertralin
mg
everi
morn
day
paroxetin
qam
min
min
min
week
lh
week
halt
sequenti
trial
patient
virtual
asymptomat
use
medic
toler
develop
drug
rel
free
advers
reaction
appreci
interact
one
anoth
two
select
serotonin
reuptak
inhibitor
ssri
given
conjointli
prefer
sertralin
zoloft
inhibit
hepat
cytochrom
thu
increas
serum
level
agent
metabol
liver
paroxetin
howev
less
like
caus
agit
gastrointestin
sideeffect
ssrl
effect
analges
effect
agent
medicin
everchang
scienc
new
research
clinic
experi
broaden
knowledg
chang
treatment
drug
therapi
requir
mani
suggest
drug
usag
made
articl
intend
educ
purpos
author
editor
publish
accept
liabil
event
neg
consequ
incur
result
inform
present
articl
claim
inform
necessarili
accur
rigid
scientif
standard
appli
medic
proof
therefor
make
warranti
express
impli
respect
materi
herein
contain
therefor
patient
urg
consult
physician
prior
follow
cours
treatment
physician
urg
check
product
inform
sheet
includ
packag
drug
plan
administ
certain
protocol
follow
conflict
manufactur
insert
discrep
aris
insert
inform
articl
physician
encourag
use
best
profession
judgement
